Dudediligence.

VolitionRx Limited

VNRXAMEX · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$474,522Sep ’24$191,657Dec ’24$246,385Mar ’25$406,688Jun ’25$627,277Sep ’25$447,034Dec ’25$985,076Mar ’26$398,657Jun ’26
Net income, by quarter
−$5.8MSep ’24−$5.8MDec ’24−$5.4MMar ’25−$6.3MJun ’25−$5.4MSep ’25−$6.3MDec ’25−$6.7MMar ’26−$7.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$90,035$306,392$775,302$1.2M$1.7M
Operating income−$28.3M−$31.8M−$36.0M−$27.0M−$21.7M
Net income−$27.0M−$30.6M−$35.7M−$27.0M−$23.4M
Operating cash flow−$20.9M−$15.3M−$18.1M−$25.9M−$19.7M
Free cash flow−$21.8M−$16.8M−$19.1M−$26.2M−$19.8M
Cash$20.6M$10.9M$20.7M$3.3M$1.1M
Debt$3.1M$3.8M$4.8M$4.8M$6.7M
Shares outstanding53.8M57.9M81.9M96.1M125.8M